Free Trial

BioAtla (BCAB) Competitors

BioAtla logo
$0.36 0.00 (-0.06%)
As of 03:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BCAB vs. ATRA, ABOS, ANRO, ORMP, IVVD, VXRT, CELU, ELUT, BYSI, and EXOZ

Should you be buying BioAtla stock or one of its competitors? The main competitors of BioAtla include Atara Biotherapeutics (ATRA), Acumen Pharmaceuticals (ABOS), Alto Neuroscience (ANRO), Oramed Pharmaceuticals (ORMP), Invivyd (IVVD), Vaxart (VXRT), Celularity (CELU), Elutia (ELUT), BeyondSpring (BYSI), and eXoZymes (EXOZ). These companies are all part of the "pharmaceutical products" industry.

BioAtla vs. Its Competitors

BioAtla (NASDAQ:BCAB) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

In the previous week, Atara Biotherapeutics had 13 more articles in the media than BioAtla. MarketBeat recorded 14 mentions for Atara Biotherapeutics and 1 mentions for BioAtla. Atara Biotherapeutics' average media sentiment score of 1.39 beat BioAtla's score of 0.00 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioAtla
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Atara Biotherapeutics
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

77.2% of BioAtla shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 11.2% of BioAtla shares are held by company insiders. Comparatively, 4.0% of Atara Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BioAtla has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500.

BioAtla has higher earnings, but lower revenue than Atara Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioAtla$11M1.90-$69.78M-$1.10-0.32
Atara Biotherapeutics$128.94M0.66-$85.40M-$0.43-28.33

Atara Biotherapeutics has a net margin of 3.07% compared to BioAtla's net margin of 0.00%. Atara Biotherapeutics' return on equity of -8.34% beat BioAtla's return on equity.

Company Net Margins Return on Equity Return on Assets
BioAtlaN/A -1,177.18% -137.51%
Atara Biotherapeutics 3.07%-8.34%6.61%

BioAtla presently has a consensus price target of $5.00, suggesting a potential upside of 1,304.49%. Atara Biotherapeutics has a consensus price target of $21.00, suggesting a potential upside of 72.41%. Given BioAtla's higher possible upside, research analysts plainly believe BioAtla is more favorable than Atara Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioAtla
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Atara Biotherapeutics
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.80

Summary

Atara Biotherapeutics beats BioAtla on 10 of the 17 factors compared between the two stocks.

Get BioAtla News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCAB vs. The Competition

MetricBioAtlaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$21.08M$3.06B$5.76B$9.75B
Dividend YieldN/A2.24%4.40%4.10%
P/E Ratio-0.3321.0030.8325.91
Price / Sales1.90392.25469.77121.46
Price / CashN/A43.2325.7828.79
Price / Book1.429.739.466.03
Net Income-$69.78M-$54.08M$3.27B$265.29M
7 Day Performance-8.39%3.12%2.37%2.86%
1 Month Performance0.34%4.57%3.88%1.23%
1 Year Performance-81.16%10.22%30.52%19.11%

BioAtla Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCAB
BioAtla
1.9813 of 5 stars
$0.36
-0.1%
$5.00
+1,304.5%
-81.2%$21.08M$11M-0.3360
ATRA
Atara Biotherapeutics
4.6507 of 5 stars
$11.48
-6.6%
$21.00
+82.9%
+72.8%$86.31M$128.94M-26.70330Positive News
ABOS
Acumen Pharmaceuticals
3.0553 of 5 stars
$1.43
+0.7%
$6.33
+342.9%
-47.4%$86.01MN/A-0.6320News Coverage
Analyst Forecast
ANRO
Alto Neuroscience
1.682 of 5 stars
$3.40
+8.4%
$8.50
+149.7%
-65.8%$85.02MN/A-1.42N/AGap Down
High Trading Volume
ORMP
Oramed Pharmaceuticals
0.9652 of 5 stars
$2.08
flat
N/A-13.7%$84.96M$1.34M-5.9410
IVVD
Invivyd
3.9717 of 5 stars
$0.58
-18.0%
$3.85
+563.8%
-48.5%$84.82M$25.38M-0.63100Analyst Forecast
Gap Up
High Trading Volume
VXRT
Vaxart
2.0989 of 5 stars
$0.36
-0.4%
$2.00
+448.5%
-63.4%$83.47M$47.40M-1.35120Gap Down
CELU
Celularity
0.692 of 5 stars
$4.15
+19.3%
$6.00
+44.6%
+19.9%$83.34M$54.22M-1.57220Analyst Upgrade
ELUT
Elutia
3.6867 of 5 stars
$2.02
flat
$8.00
+296.0%
-48.1%$83.05M$23.68M-1.91180Gap Up
BYSI
BeyondSpring
N/A$1.85
-8.4%
N/A-8.3%$81.47M$1.75M0.0080Gap Up
High Trading Volume
EXOZ
eXoZymes
N/A$9.76
+0.6%
N/AN/A$81.36M$70K0.0029News Coverage
Positive News
Gap Up

Related Companies and Tools


This page (NASDAQ:BCAB) was last updated on 8/25/2025 by MarketBeat.com Staff
From Our Partners